REDWOOD CITY, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Please note the addition of citations at the end of the release dated Sept. 4, 2022. The updated release reads: CONVERT CLINICAL TRIAL DATA ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pulmonx®, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial ...
REDWOOD CITY, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the ...
(MENAFN- GlobeNewsWire - Nasdaq) CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study ...
The reported data suggest that patients with collateral ventilation may be able to undergo successful treatment with Zephyr Endobronchial Valves following closure of collateral air channels with the ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results